ProBioGen and VarmX B.V. Announce Collaboration for Advanced Cell Line Development

Source Summary

BERLIN, Germany and LEIDEN, The Netherlands, July 28, 2026 / Biotech Newswire / -- ProBioGen today announced a new collaboration with VarmX B.V. for the development of their second therapeutic Factor X candidate. The partnership will advance VarmX's innovative Factor X program through cell line development using ProBioGen's proprietary HEK293 host cell line platform. This collaboration builds upon ProBioGen's extensive expertise in coagulation factor development, including successful programs with, for example, Factor VII and Factor VIII therapeutics. "We are excited to partner with VarmX on this compelling and demanding molecule," said Dr. Volker ...